Auranofin ((1 -thio-/3-D-glucopyranose 2,3,4,6-tetraacetato-S)(triethylphosphine)gold(I)) is an orally active drug for the treatment of rheumatoid arthritis. Auranofin reacts with HC1 in aqueous solution and in 50% methanol/water to form chloro(triethylphosphine)gold(I) (ClAuPEt3) and with ClAuPEt3 to form a thiolate-bridged dinuclear gold complex with two gold triethylphosphine moieties bound to a single thioglucose ligand ((µ-1-thio-d-D-glucopyranose 2,3,4,6-tetraacetato-S:S)bis(triethylphosphine)digold(I) chloride). The thermodynamics and kinetics of these reactions have been studied in water and in 50% methanol/water. The equilibrium constants for the formation of ClAuPEt3 are 4.6 X 10~4 M"1 in water and 2.0 x 10"3 M'1 in 50% methanol/water while the equilibrium constant for the formation of the thiolate-bridged digold complex is 1.2 X 103 (water), 1.3 X 102 (50% methanol/water), and 0.7 X 102 (95% methanol). The kinetics for the formation of the thiolate-bridged digold complex are too rapid to be observed by ordinary mixing techniques, but the chloride replacement of tetraacetylthioglucose could be studied via the stopped-flow method. For the reaction at 25 °C in 1.0 M Cl", kobsd = 385[H+] in the mixed-solvent medium and kobid = 210[H+] + 4.3 X 105 [HTATG] in water in the presence of excess tetraacetylthioglucose.